|сгенерировать QR код
Открытый доступ
Только для подписчиков
Гиперурикемия и нефро-церебральный континуум
https://doi.org/10.36485/1561-6274-2025-29-2-9-16
EDN: FQWGFC
Аннотация
Мочевая кислота играет важную роль в развитии заболеваний почек и цереброваскулярных заболеваний. Почки играют решающую роль в регулировании уровня мочевой кислоты в сыворотке крови, на их долю приходится 60–70 % экскреции мочевой кислоты. В норме почки реабсорбируют примерно 90 % мочевой кислоты, отфильтрованной клубочками в проксимальных канальцах. Мочевая кислота является продуктом распада пуринов и может выполнять множество физиологических функций, включая антиоксидантные и нейропротекторные, поддержание кровяного давления при приеме с низким содержанием соли и модуляцию иммунитета. Однако избыточная продукция мочевой кислоты и/или дисбаланс почечной секреции и реабсорбции мочевой кислоты, и/или недостаточная экскреция внепочечной мочевой кислоты, например, в кишечнике, будут способствовать гиперурикемии, которая является распространенным метаболическим заболеванием. Гиперурикемия и подагра связаны с многочисленными сердечно-сосудистыми и почечными нарушениями, например, гипертонией, инфарктом миокарда, инсультом, ожирением, гиперлипидемией, сахарным диабетом 2 типа и хроническими заболеваниями почек. В статье обсуждается нефро-церебральный континуум при гиперурикемии.
Ключевые слова
Об авторах
Ф. А. Юсупов
Ошский государственный университет
Кыргызстан
Кыргызстан
Проф. Юсупов Фуркат Абдулахатович - д-р мед. наук. Кафедра неврологии, психиатрии и нейрохирургии медицинского факультета Ошского государственного университета. Зав. каф., член правления Общества специалистов по хронической болезни почек Кыргызстана.
714000, Ош, ул. Ленина, д. 331. Тел.: (+996) 557202071
И. Т. Ыдырысов
Ошский государственный университет
Кыргызстан
Кыргызстан
Проф. Ыдырысов Исматилла Токтосунович - д-р мед. наук. Ошский государственный университет, декан медицинского факультета.
714000, Ош, ул. Ленина, д. 331. Тел.: (+996) 772334433
А. А. Юлдашев
Ошский государственный университет
Кыргызстан
Кыргызстан
Юлдашев Акмал Акбарович - Кафедра неврологии, психиатрии и нейрохирургии медицинского факультета Ошского государственного университета, аспирант.
714000, Ош, ул. Ленина, д. 331. Тел.: (+996) 559062491
Список литературы
1. Якупова СП. Подагра. Новые возможности диагностики и лечения. Терапевтический архив 2018;90(5):88–92. doi: 10.26442/terarkh201890588-92
2. Zhao Z, Liu J, Yuan L, Yang Z, Kuang P, Liao H, Luo J, Feng H, Zheng F, Chen Y, Wu T, Guo J, Cao Y, Yang Y, Lin C, Zhang Q, Chen J, Pang J. Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents. Eur J Med Chem 2022 Nov 15;242:114682. doi: 10.1016/j.ejmech.2022.114682. Epub 2022 Aug 18. PMID: 36001935
3. Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis 2012;19(6):358–371. doi:10.1053/j.ackd.2012.07.009
4. Matsumura N, Aoyama K. Glutathione-Mediated Neuroprotective Effect of Purine Derivatives. Int J Mol Sci 2023 Aug 22;24(17):13067. doi: 10.3390/ijms241713067. PMID: 37685879; PMCID: PMC10487553
5. Tana C, Busetto L, Di Vincenzo A, Ricci F, Ticinesi A, Lauretani F, Nouvenne A, Giamberardino MA, Cipollone F, Vettor R, Meschi T. Management of hyperuricemia and gout in obese patients undergoing bariatric surgery. Postgrad Med 2018 Aug;130(6):523–535. doi: 10.1080/00325481.2018.1485444. Epub 2018 Jun 22. PMID: 29888674
6. Esparza Martín N, García Nieto V. Hypouricemia and tubular transport of uric acid. Nefrologia 2011;31(1):44–50. doi: 10.3265/Nefrologia.pre2010.Oct.10588. PMID: 21270912
7. Yip K, Cohen RE, Pillinger MH. Asymptomatic hyperuricemia: is it really asymptomatic? Curr Opin Rheumatol 2020 Jan;32(1):71–79. doi: 10.1097/BOR.0000000000000679. PMID: 31688126
8. Юсупов ФА, Юлдашев АА. Ишемический инсульт: фокус на гиперурикемию. Нефрология 2024;28(2):104–110. https://doi.org/10.36485/1561-6274-2024-28-2-104-110. EDN: TNHSRY
9. Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res 2020;12(7):3167–3181. Published 2020 Jul 15
10. Williams LA. The History, Symptoms, Causes, Risk Factors, Types, Diagnosis, Treatments, and Prevention of Gout, Part 2. Int J Pharm Compd 2019 Jan-Feb;23(1):14–21. PMID: 30668531
11. Wu X, You C. The biomarkers discovery of hyperuricemia and gout: proteomics and metabolomics. PeerJ 2023;11:e14554. Published 2023 Jan 6. doi:10.7717/peerj.14554
12. Yokokawa H, Fukuda H, Suzuki A et al. Association Between Serum Uric Acid Levels/Hyperuricemia and Hypertension Among 85,286 Japanese Workers. J Clin Hypertens (Greenwich) 2016;18(1):53–59. doi:10.1111/jch.12627
13. Mallat SG, Al Kattar S, Tanios BY, Jurjus A. Hyperuricemia, Hypertension, and Chronic Kidney Disease: an Emerging Association. Curr Hypertens Rep 2016 Oct;18(10):74. doi: 10.1007/s11906-016-0684-z. PMID: 27696189
14. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ. A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002 Dec;13(12):2888–2897. doi: 10.1097/01.asn.0000034910.58454.fd. PMID: 12444207
15. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ. Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001 Nov;38(5):1101–1106. doi: 10.1161/hy1101.092839. PMID: 11711505
16. Mazzali M, Kanellis J, Han L, Feng L, Xia YY, Chen Q, Kang DH, Gordon KL, Watanabe S, Nakagawa T, Lan HY, Johnson RJ. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002 Jun;282(6):F991–997. doi: 10.1152/ajprenal.00283.2001. PMID: 11997315
17. Sánchez-Lozada LG, Tapia E, Avila-Casado C, Soto V, Franco M, Santamaría J, Nakagawa T, Rodríguez-Iturbe B, Johnson RJ, Herrera-Acosta J. Mild hyperuricemia induces glomerular hypertension in normal rats. Am J Physiol Renal Physiol 2002 Nov;283(5):F1105–1110. doi: 10.1152/ajprenal.00170.2002. PMID: 12372787
18. Sánchez-Lozada LG, Tapia E, Santamaría J, Avila-Casado C, Soto V, Nepomuceno T, Rodríguez-Iturbe B, Johnson RJ, Herrera-Acosta J. Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 2005 Jan;67(1):237–247. doi: 10.1111/j.15231755.2005.00074.x. PMID: 15610247
19. Obermayr RP, Temml C, Gutjahr G, Knechtelsdorfer M, Oberbauer R, Klauser-Braun R. Elevated uric acid increases the risk for kidney disease. J Am Soc Nephrol 2008 Dec;19(12):2407– 2413. doi: 10.1681/ASN.2008010080. Epub 2008 Sep 17. PMID: 18799720; PMCID: PMC2588108
20. Braga TT, Foresto-Neto O, Camara NOS. The role of uric acid in inflammasome-mediated kidney injury. Curr Opin Nephrol Hypertens 2020 Jul;29(4):423–431. doi: 10.1097/MNH.0000000000000619. PMID: 32452918
21. Liu N, Wang L, Yang T et al. EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy. J Am Soc Nephrol 2015 Nov;26(11):2716–2729. doi: 10.1681/ASN.2014080793
22. Zhou Y, Fang L, Jiang L et al. Uric acid induces renal inflammation via activating tubular NF-κB signaling pathway. PLoS One 2012;7(6):e39738. doi: 10.1371/journal.pone.0039738
23. Su HY, Yang C, Liang D et al. Research Advances in the Mechanisms of Hyperuricemia-Induced Renal Injury. Biomed Res Int 2020 Jun 26;2020:5817348. doi: 10.1155/2020/5817348
24. Gustafsson D, Unwin R. The pathophysiology of hyperuricaemia and its possible relationship to cardiovascular disease, morbidity and mortality. BMC Nephrol 2013 Jul 29;14:164. doi: 10.1186/1471-2369-14-164
25. Zhang Y, Yamamoto T, Hisatome I et al. Uric acid induces oxidative stress and growth inhibition by activating adenosine monophosphate-activated protein kinase and extracellular signal-regulated kinase signal pathways in pancreatic β cells. Mol Cell Endocrinol 2013 Aug 15;375(1–2):89–96. doi: 10.1016/j.mce.2013.04.027
26. Doehner W, Schoene N, Rauchhaus M et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002 Jun 4;105(22):2619–2624. doi: 10.1161/01.cir.0000017502.58595.ed. PMID: 12045167
27. Lytvyn Y, Perkins BA, Cherney DZ. Uric acid as a biomarker and a therapeutic target in diabetes. Can J Diabetes 2015 Jun;39(3):239–246. doi: 10.1016/j.jcjd.2014.10.013. Epub 2015 Jan 16. PMID: 25600084
28. Yang L, Chang B, Guo Y, Wu X, Liu L. The role of oxidative stress-mediated apoptosis in the pathogenesis of uric acid nephropathy. Ren Fail 2019 Nov;41(1):616–622. doi: 10.1080/0886022X.2019.1633350
29. Cristóbal-García M, García-Arroyo FE, Tapia E et al. Renal oxidative stress induced by long-term hyperuricemia alters mitochondrial function and maintains systemic hypertension. Oxid Med Cell Longev 2015;2015:535686. doi: 10.1155/2015/535686. Epub 2015 Mar 31. PMID: 25918583; PMCID: PMC4396880
30. Fan S, Zhang P, Wang AY et al. Hyperuricemia and its related histopathological features on renal biopsy. BMC Nephrol 2019 Mar 18;20(1):95. doi: 10.1186/s12882-019-1275-4
31. Safar ME, London GM. Therapeutic studies and arterial stiffness in hypertension: recommendations of the European Society of Hypertension. The Clinical Committee of Arterial Structure and Function. Working Group on Vascular Structure and Function of the European Society of Hypertension. J Hypertens 2000 Nov;18(11):1527–1535. doi: 10.1097/00004872-20001811000001. PMID: 11081763
32. Blacher J, Pannier B, Guerin AP et al. Carotid arterial stiffness as a predictor of cardiovascular and all-cause mortality in end-stage renal disease. Hypertension 1998 Sep;32(3):570–574. doi: 10.1161/01.hyp.32.3.570. PMID: 9740628
33. Bank AJ, Wang H, Holte JE et al. Contribution of collagen, elastin, and smooth muscle to in vivo human brachial artery wall stress and elastic modulus. Circulation 1996 Dec 15;94(12):3263– 3270. doi: 10.1161/01.cir.94.12.3263. PMID: 8989139
34. Mitchell GF, van Buchem MA, Sigurdsson S et al. Arterial stiffness, pressure and flow pulsatility and brain structure and function: the Age, Gene/Environment Susceptibility-Reykjavik study. Brain 2011 Nov;134(Pt 11):3398–3407. doi: 10.1093/brain/awr253. PMID: 22075523; PMCID: PMC3212721
35. Sedaghat S, Mattace-Raso FU, Hoorn EJ et al. Arterial Stiffness and Decline in Kidney Function. Clin J Am Soc Nephrol 2015 Dec 7;10(12):2190–2197. doi: 10.2215/CJN.03000315
36. Enomoto A, Kimura H, Chairoungdua A et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002 May 23;417(6887):447–452. doi: 10.1038/nature742
37. Sánchez-Lozada LG, Soto V, Tapia E, Avila-Casado C, Sautin YY, Nakagawa T, Franco M, Rodríguez-Iturbe B, Johnson RJ. Role of oxidative stress in the renal abnormalities induced by experimental hyperuricemia. Am J Physiol Renal Physiol 2008 Oct;295(4):F1134–1141. doi: 10.1152/ajprenal.00104.2008
38. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension 2003 Jun;41(6):1287–1293. doi: 10.1161/01.HYP.0000072820.07472.3B
39. Xie H, Sun J, Chen Y, Zong M, Li S, Wang Y. EGCG Attenuates Uric Acid-Induced Inflammatory and Oxidative Stress Responses by Medicating the NOTCH Pathway. Oxid Med Cell Longev 2015;2015:214836. doi: 10.1155/2015/214836. Epub 2015 Oct 11. PMID: 26539255; PMCID: PMC4619967
40. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990 Dec 20–27;348(6303):730–732. doi: 10.1038/348730a0
41. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML. Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 2008 Feb;26(2):269–275. doi: 10.1097/HJH.0b013e3282f240bf
42. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, Lan H, Mazzali M, Johnson RJ. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002 Sep;40(3):355–360. doi: 10.1161/01.hyp.0000028589.66335.aa
43. Johnson RJ, Nakagawa T, Jalal D, Sánchez-Lozada LG, Kang DH, Ritz E. Uric acid and chronic kidney disease: which is chasing which? Nephrol Dial Transplant 2013 Sep;28(9):2221– 2228. doi: 10.1093/ndt/gft029
44. Дикштейн ЕА, Васленко ИВ, Синяченко ОВ и др. Морфологические изменения клубочков почек при подагре. Архив патологии 1986;48(9):54–58
45. Shi Y, Xu L, Tao M, Fang L, Lu J, Gu H, Ma S, Lin T, Wang Y, Bao W, Qiu A, Zhuang S, Liu N. Blockade of enhancer of zeste homolog 2 alleviates renal injury associated with hyperuricemia. Am J Physiol Renal Physiol 2019 Mar 1;316(3):F488–F505. doi: 10.1152/ajprenal.00234.2018
46. Zavadil J, Böttinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 2005 Aug 29;24(37):5764–5774. doi: 10.1038/sj.onc.1208927
47. Kim SM, Choi YW, Seok HY, Jeong KH, Lee SH, Lee TW, Ihm CG, Lim SJ, Moon JY. Reducing serum uric acid attenuates TGF-β1-induced profibrogenic progression in type 2 diabetic nephropathy. Nephron Exp Nephrol 2012;121(3–4):e109–121. doi: 10.1159/000343567
48. Zoppini G, Targher G, Chonchol M, Ortalda V, Abaterusso C, Pichiri I, Negri C, Bonora E. Serum uric acid levels and incident chronic kidney disease in patients with type 2 diabetes and preserved kidney function. Diabetes Care 2012 Jan;35(1):99–104. doi: 10.2337/dc11-1346
49. Domrongkitchaiporn S, Sritara P, Kitiyakara C, Stitchantrakul W, Krittaphol V, Lolekha P, Cheepudomwit S, Yipintsoi T. Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J Am Soc Nephrol 2005 Mar;16(3):791–799. doi: 10.1681/ASN.2004030208
50. Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, Kestenbaum B, Carney JK, Fried LF. Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007 Aug;50(2):239–247. doi: 10.1053/j.ajkd.2007.05.013
51. Hsu CY, Iribarren C, McCulloch CE, Darbinian J, Go AS. Risk factors for end-stage renal disease: 25-year follow-up. Arch Intern Med 2009 Feb 23;169(4):342–350. doi: 10.1001/archinternmed.2008.605
52. Bellomo G, Venanzi S, Verdura C, Saronio P, Esposito A, Timio M. Association of uric acid with change in kidney function in healthy normotensive individuals. Am J Kidney Dis 2010 Aug;56(2):264–272. doi: 10.1053/j.ajkd.2010.01.019
53. Sonoda H, Takase H, Dohi Y, Kimura G. Uric acid levels predict future development of chronic kidney disease. Am J Nephrol 2011;33(4):352–357. doi: 10.1159/000326848
54. Uchida S, Chang WX, Ota T, Tamura Y, Shiraishi T, Kumagai T, Shibata S, Fujigaki Y, Hosoyamada M, Kaneko K, Shen ZY, Fujimori S. Targeting Uric Acid and the Inhibition of Progression to EndStage Renal Disease-A Propensity Score Analysis. PLoS One 2015 Dec 23;10(12):e0145506. doi: 10.1371/journal.pone.0145506
55. Rodenbach KE, Schneider MF, Furth SL, MoxeyMims MM, Mitsnefes MM, Weaver DJ, Warady BA, Schwartz GJ. Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study. Am J Kidney Dis 2015 Dec;66(6):984–992. doi: 10.1053/j.ajkd.2015.06.015
56. Iseki K, Ikemiya Y, Inoue T et al. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort. Am J Kidney Dis 2004 Oct;44(4):642–650
57. Li L, Yang C, Zhao Y, Zeng X, Liu F, Fu P. Is hyperuricemia an independent risk factor for new-onset chronic kidney disease?: A systematic review and meta-analysis based on observational cohort studies. BMC Nephrol 2014 Jul 27;15:122. doi: 10.1186/14712369-15-122
58. Park JH, Jo YI, Lee JH. Renal effects of uric acid: hyperuricemia and hypouricemia. Korean J Intern Med 2020 Nov;35(6):1291–1304. doi: 10.3904/kjim.2020.410
59. Rosolowsky ET, Ficociello LH, Maselli NJ et al. High-normal serum uric acid is associated with impaired glomerular filtration rate in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2008 May;3(3):706–713. doi: 10.2215/CJN.04271007
60. Jhee JH, Joo YS, Han SH et al. High muscle-to-fat ratio is associated with lower risk of chronic kidney disease development. J Cachexia Sarcopenia Muscle 2020 Jun;11(3):726–734. doi: 10.1002/jcsm.12549
61. Kim JK, Kim SG, Oh JE et al. Impact of sarcopenia on longterm mortality and cardiovascular events in patients undergoing hemodialysis. Korean J Intern Med 2019 May;34(3):599–607. doi: 10.3904/kjim.2017.083
62. Srivastava A, Kaze AD, McMullan CJ et al. Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD. Am J Kidney Dis 2018 Mar;71(3):362–370. doi: 10.1053/j.ajkd.2017.08.017
63. Cha RH, Kim SH, Bae EH et al. Physicians’ perceptions of asymptomatic hyperuricemia in patients with chronic kidney disease: A questionnaire survey. Kidney Res Clin Pract 2019 Sep 30;38(3):373–381. doi: 10.23876/j.krcp.19.007
64. Shin DH. To treat or not to treat asymptomatic hyperuricemia in chronic kidney disease. Kidney Res Clin Pract 2019 Sep 30;38(3):257–259. doi: 10.23876/j.krcp.19.074. PMID: 31474091
65. Cutler RG, Camandola S, Feldman NH et al. Uric acid enhances longevity and endurance and protects the brain against ischemia. Neurobiol Aging 2019 Mar;75:159–168. doi: 10.1016/j.neurobiolaging.2018.10.031
66. Jensen NJ, Wodschow HZ, Nilsson M, Rungby J. Effects of Ketone Bodies on Brain Metabolism and Function in Neurodegenerative Diseases. Int J Mol Sci 2020 Nov 20;21(22):8767. doi: 10.3390/ijms21228767
67. Otani N, Hoshiyama E, Ouchi M et al. Uric acid and neurological disease: a narrative review. Front Neurol 2023 Jun 1;14:1164756. doi: 10.3389/fneur.2023.1164756
68. Dong Y, Shi H, Chen X et al. Serum uric acid and risk of stroke: a dose-response meta-analysis. J Clin Biochem Nutr 2021 May;68(3):221–227. doi: 10.3164/jcbn.20-94
69. Mentis AA, Dardiotis E, Efthymiou V, Chrousos GP. Nongenetic risk and protective factors and biomarkers for neurological disorders: a meta-umbrella systematic review of umbrella reviews. BMC Med 2021 Jan 13;19(1):6. doi: 10.1186/s12916-020-01873-7
70. Holme I, Aastveit AH, Hammar N et al. Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). J Intern Med 2009 Dec;266(6):558–570. doi: 10.1111/j.1365-2796.2009.02133.x
71. Schretlen DJ, Inscore AB, Vannorsdall TD et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology 2007 Oct 2;69(14):1418–1423. doi: 10.1212/01.wnl.0000277468.10236.f1
72. Wong KY, MacWalter RS, Fraser HW et al. Eur Heart J 2002 May;23(10):788–793. doi: 10.1053/euhj.2001.2970
73. Kim SY, Guevara JP, Kim KM et al. Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 2009 Jul 15;61(7):885–892. doi: 10.1002/art.24612
74. Malhotra R, Katz R, Jotwani V et al. Estimated GFR Variability and Risk of Cardiovascular Events and Mortality in SPRINT (Systolic Blood Pressure Intervention Trial). Am J Kidney Dis 2021 Jul;78(1):48–56. doi: 10.1053/j.ajkd.2020.10.016
75. Mone P, Pansini A. Gait Speed Test and Cognitive Decline in Frail Women With Acute Myocardial Infarction. Am J Med Sci 2020 Nov;360(5):484–488. doi: 10.1016/j.amjms.2020.03.021
76. Viggiano D, Wagner CA, Martino G, Nedergaard M, Zoccali C, Unwin R, Capasso G. Mechanisms of cognitive dysfunction in CKD. Nat Rev Nephrol 2020 Aug;16(8):452–469. doi: 10.1038/s41581-020-0266-9
77. Afsar B, Sag AA, Yalcin CE, Kaya E, Siriopol D, Goldsmith D, Covic A, Kanbay M. Brain-kidney cross-talk: Definition and emerging evidence. Eur J Intern Med 2016 Dec;36:7–12. doi: 10.1016/j.ejim.2016.07.032
78. Murray AM. The brain and the kidney connection: A model of accelerated vascular cognitive impairment. Neurology 2009 Sep 22;73(12):916–917. doi: 10.1212/WNL.0b013e3181b99a2e. Epub 2009 Aug 19. PMID: 19692675
79. Lu R, Kiernan MC, Murray A, Rosner MH, Ronco C. Kidneybrain crosstalk in the acute and chronic setting. Nat Rev Nephrol 2015 Dec;11(12):707–719. doi: 10.1038/nrneph.2015.131
80. Tana C, Ticinesi A, Prati B, Nouvenne A, Meschi T. Uric Acid and Cognitive Function in Older Individuals. Nutrients 2018; 10(8):975. https://doi.org/10.3390/nu10080975
81. Viggiano D, Gigliotti G, Vallone G, Giammarino A, Nigro M, Capasso G. Urate-Lowering Agents in Asymptomatic Hyperuricemia: Role of Urine Sediment Analysis and Musculoskeletal Ultrasound. Kidney Blood Press Res 2018;43(2):606–615. doi: 10.1159/000489145. Epub 2018 Apr 19. PMID: 29689561
82. Chamorro A, Planas AM, Muner DS, Deulofeu R. Uric acid administration for neuroprotection in patients with acute brain ischemia. Med Hypotheses 2004;62(2):173–176. doi: 10.1016/S0306-9877(03)00324-4. PMID: 14962621
Рецензия
Для цитирования:
Юсупов Ф.А., Ыдырысов И.Т., Юлдашев А.А. Гиперурикемия и нефро-церебральный континуум. Нефрология. 2025;29(2):9-16. https://doi.org/10.36485/1561-6274-2025-29-2-9-16. EDN: FQWGFC
For citation:
Yusupov F.A., Ydyrysov I.T., Yuldashev A.A. Hyperuricemia and the nephrocerebral continuum. Nephrology (Saint-Petersburg). 2025;29(2):9-16. (In Russ.) https://doi.org/10.36485/1561-6274-2025-29-2-9-16. EDN: FQWGFC
Просмотров:
77
Послать статью по эл. почте 